Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 24827895)

1.

The authors' reply.

Melancon JK.

Transplantation. 2014 May 27;97(10):e60-1. doi: 10.1097/TP.0000000000000135. No abstract available.

PMID:
24827895
2.

Regarding outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis.

Parsikia A, Karipineni F, Ortiz J.

Transplantation. 2014 May 27;97(10):e60. doi: 10.1097/TP.0000000000000091. No abstract available.

PMID:
24827894
3.

Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis.

Melancon K, Mulgaonkar SP, Delcoro C, Wiland A, McCague K, Shihab FS.

Transplantation. 2013 Dec 27;96(12):1073-81. doi: 10.1097/TP.0b013e3182a486f5.

4.

Histological progression of chronic renal allograft injury comparing sirolimus and mycophenolate mofetil-based protocols. A single-center, prospective, randomized, controlled study.

Blydt-Hansen TD, Gibson IW, Birk PE.

Pediatr Transplant. 2010 Nov;14(7):909-18. doi: 10.1111/j.1399-3046.2010.01374.x. Epub 2010 Sep 29.

PMID:
20880093
5.

Long-term renal allograft survival after posttransplantation diagnosis of primary hyperoxaluria.

Roberts V, Rajakumar SV, Crikis S, Dwyer KM, Hill PA, Goodman DJ.

Transplantation. 2013 Mar 27;95(6):e35-6. doi: 10.1097/TP.0b013e3182827a22. No abstract available.

PMID:
23507654
6.

Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.

Moscarelli L, Caroti L, Antognoli G, Zanazzi M, Di Maria L, Carta P, Minetti E.

Clin Transplant. 2013 Jul-Aug;27(4):546-54. doi: 10.1111/ctr.12151. Epub 2013 Jun 13.

PMID:
23758330
7.

Simultaneous heart and kidney transplantation from a single donor.

Hsu RB, Tsai MK, Lee PH, Lee CM, Chen MF, Wang SS, Lin FY, Chu SH.

Eur J Cardiothorac Surg. 2008 Dec;34(6):1179-84. doi: 10.1016/j.ejcts.2008.08.018. Epub 2008 Oct 1.

PMID:
18835781
8.

No recurrence of Kaposi's sarcoma in a case of renal retransplantation under a calcineurin inhibitor free immunosuppressive regimen: first report.

Segoloni GP, Giraudi R, Messina M, Rossetti M, Biancone L, Leonardi G, Piccoli GB, Magnano A, Gai M.

Transpl Int. 2007 Apr;20(4):395-6. No abstract available.

PMID:
17326783
9.

Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.

Flechner SM, Kobashigawa J, Klintmalm G.

Clin Transplant. 2008 Jan-Feb;22(1):1-15. doi: 10.1111/j.1399-0012.2007.00739.x. Review.

PMID:
18217899
10.

Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating donor kidney transplantation.

Diekmann F, Campistol JM, Saval N, Gutiérrez-Dalmau A, Arellano EM, Crespo M, Rossich E, Esforzado N, Cofán F, Ricart MJ, Torregrosa JV, Oppenheimer F.

Transplantation. 2007 Aug 15;84(3):429-32.

PMID:
17700171
11.

Early experience using calcineurin-free protocol in recipients of high-risk cadaver renal transplants.

El-Sabrout R, Delaney V, Butt F, Qadir M, Rashid I, Hanson P, Butt K.

Transplant Proc. 2002 Aug;34(5):1627-8. No abstract available.

PMID:
12176512
12.

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

Tedesco Silva H Jr, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, Walker R, Wang Z, Zibari G, Kim YS.

Am J Transplant. 2010 Jun;10(6):1401-13. doi: 10.1111/j.1600-6143.2010.03129.x. Epub 2010 Apr 28.

13.

Different models of transition to adult care after pediatric kidney transplantation: a comparative study.

Pape L, Lämmermühle J, Oldhafer M, Blume C, Weiss R, Ahlenstiel T.

Pediatr Transplant. 2013 Sep;17(6):518-24. doi: 10.1111/petr.12102. Epub 2013 Jun 4.

PMID:
23730905
14.

Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits.

Gruber SA, Doshi MD.

Transplantation. 2010 May 15;89(9):1161-2. doi: 10.1097/TP.0b013e3181d1f238. No abstract available.

PMID:
20440195
15.

Corticosteroids in recurrence of glomerular disease in renal transplantation: do we know the right questions to ask?

Lau RL, Hanudel MR, Ettenger RB.

Pediatr Transplant. 2012 Nov;16(7):684-7. doi: 10.1111/j.1399-3046.2012.01776.x. Epub 2012 Sep 4. No abstract available.

PMID:
22943665
16.

To kidney or not to kidney, when … is the question.

Baker TB, Abecassis M, Levitsky J.

Liver Transpl. 2012 Aug;18(8):875-7. doi: 10.1002/lt.23462. No abstract available.

17.

Effect of sirolimus withdrawal in patients with deteriorating renal function.

Kaplan B, Schold J, Srinivas T, Womer K, Foley DP, Patton P, Howard R, Meier-Kriesche HU.

Am J Transplant. 2004 Oct;4(10):1709-12.

18.

A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.

Picard N, Prémaud A, Rousseau A, Le Meur Y, Marquet P.

Br J Clin Pharmacol. 2006 Oct;62(4):477-84.

19.

The role of Certican (everolimus, rad) in the many pathways of chronic rejection.

Nashan B.

Transplant Proc. 2001 Nov-Dec;33(7-8):3215-20. No abstract available.

PMID:
11750380
20.

Inferior early posttransplant outcomes for recipients of right versus left deceased and living donor kidneys.

Hsu JW, Reese PP, Naji A, Levine MH, Abt PL.

Am J Transplant. 2013 Nov;13(11):3048. doi: 10.1111/ajt.12473. Epub 2013 Sep 18. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk